



Supplementary Figure 1. Number of molecules with DDI by drug classes among HCV diagnosed patients in 2018. (A) Contraindicated DDIs with DAA regimens. (B) Potential DDIs with DAA regimens. Count indicated as the number of DDIs recorded between medications in the categories and the DAA regimens. DDI, drug-drug interaction; DAA, direct-acting antiviral; LDV, ledipasvir; SOF, sofosbuvir; VEL, velpatasvir; GLE, glecaprevir; PIB, pibrentasvir; HIV, human immunodeficiency virus.